← United States · Coverage record
US · SEC FORM 4
ASTRAZENECA PLC
AZN · NYSE · CIK 0000901832 · Healthcare · Drug Manufacturers—General
INSIDER SIGNAL
1 qualifying P purchase group
in the current 180-day scoring window
8 Form 4 transaction lines observed in the same window
1 sales · 6 option, withholding, award, gift or other lines
WHY NO ACTIVE SIGNAL?
Score anatomy
No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.
Why is there no score?
- No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
- Sales and other Form 4 activity remain visible as context and do not create a negative score.
Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.
Insider activity timeline
Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.
—
Purchase breadth & concentration
Roles in the peak window: See Remarks. Concentration uses priced qualifying P lines only and does not change the saved score.
SIGNAL HISTORY
Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2026-08-08 · Sharma Mani.
Recent Form 4 activity
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
Market context
Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.
Price performance
- 1M
- -1.1%
- 3M
- -3.8%
- 6M
- -21.7%
- 12M
- -6.9%
Volatility & liquidity
- Volatility
- 26.8%
- Beta
- —
- Avg daily value
- USD 524.2M
Valuation
- Market cap
- —
- P/E
- —
Fundamentals
- Profit margin
- —
- ROE
- —
- Industry
- Drug Manufacturers—General
Market data
Price data up to: 2026-10-12 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · Status: PASS
Short interest
Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.
- Shares short
- 2,618,811
- Previous report
- 2,087,754
- Avg daily volume
- 2,810,335
- Days to cover
- ≤ 1.0
FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.
Historical equity purchases
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-08-08 | Sharma Mani | Purchase (P) | Ordinary Shares | 20 | USD 160.57 | USD 3,248 | SEC filing ↗ |
Form 4 evidence
9 transaction lines in the latest 365-day window; 9 in local history.
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-10-06 | Sharma Mani | Award / grant (A) | Ordinary Shares | 2 | USD 159.80 | USD 320 | SEC filing ↗ |
| 2026-09-08 | Sharma Mani | Award / grant (A) | Ordinary Shares | 1 | USD 162.60 | USD 163 | SEC filing ↗ |
| 2026-08-08 | Sharma Mani | Purchase (P) | Ordinary Shares | 20 | USD 160.57 | USD 3,248 | SEC filing ↗ |
Show recent Form 4 evidence (9 grouped rows)
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-10-06 | Sharma Mani | Award / grant (A) | Ordinary Shares | 2 | USD 159.80 | USD 320 | SEC filing ↗ |
| 2026-09-08 | Sharma Mani | Award / grant (A) | Ordinary Shares | 1 | USD 162.60 | USD 163 | SEC filing ↗ |
| 2026-08-08 | Sharma Mani | Purchase (P) | Ordinary Shares | 20 | USD 160.57 | USD 3,248 | SEC filing ↗ |
| 2026-08-06 | Sharma Mani | Award / grant (A) | Ordinary Shares | 2 | USD 163.34 | USD 327 | SEC filing ↗ |
| 2026-07-06 | Sharma Mani | Award / grant (A) | Ordinary Shares | 2 | USD 190.43 | USD 381 | SEC filing ↗ |
| 2026-06-08 | Sharma Mani | Award / grant (A) | Ordinary Shares | 1 | USD 179.75 | USD 180 | SEC filing ↗ |
| 2026-05-20 | Sharma Mani | Sale (S) | Ordinary Shares | 11,893 | USD 185.78 | USD 2,209,482 | SEC filing ↗ |
| 2026-05-06 | Sharma Mani | Award / grant (A) | Ordinary Shares | 1 | USD 186.28 | USD 186 | SEC filing ↗ |
| 2026-04-07 | Sharma Mani | Award / grant (A) | Ordinary Shares | 1 | USD 196.03 | USD 196 | SEC filing ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
Snapshot & identity
| Snapshot date | 2026-10-18 |
|---|---|
| Ranking version | US-v1.2 |
| Data quality | PASS ELIGIBLE · — |
| Ticker | AZN |
| CIK | 0000901832 |
| Sector | Healthcare |
| Industry | Drug Manufacturers—General Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| Exchange | NYSE |
Data coverage
| Local Form 4 history | 9 transaction lines from 2026-04-07 to 2026-10-06 1 P purchase lines · 1 S sale lines · 7 other lines |
|---|---|
| SEC company submissions | Open SEC filings ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.